The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Quantitative pre-treatment assessment of trastuzumab deruxtecan (T-DXd) antibody target (HER2) and payload target (topoisomerase 1, Topo1) to predict outcomes in metastatic breast cancer (MBC).
 
Paolo Tarantino
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Genentech/Roche; Gilead Sciences; Lilly; Novartis
Research Funding - AstraZeneca
 
Se Kim
No Relationships to Disclose
 
Melissa Hughes
No Relationships to Disclose
 
Ashka Patel
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Kalie Smith
No Relationships to Disclose
 
Fara Brasó-Maristany
Employment - Reveal Genomics
Patents, Royalties, Other Intellectual Property - Patents filed: PCT/EP2022/086493, PCT/EP2023/060810, EP23382703 and EP23383369
 
Laia Pare
Patents, Royalties, Other Intellectual Property - IN VITRO METHOD FOR PREDICTING LONGEVITY IN PATIENTS SUFFERING FROM BREAST CANCER EP 23 383 369.8; IN VITRO METHOD FOR THE PROGNOSIS OF PATIENTS SUFFERING FROM HER2-POSITIVE BREAST CANCER PCT/EP2021/070788; IN VITRO METHOD FOR THE PROGNOSIS OF PATIENTS SUFFERING FROM TRIPLE-NEGATIVE BREAST CANCER EP 23 382 703.9 PCT/EP2024/068197
 
Justin Davis
Employment - Ignite Proteomics
 
Claudius Mueller
Employment - Ignite Proteomics
 
Brian Corgiat
Employment - Ignite Proteomics
 
Mercedes Marín-Aguilera
Employment - Reveal Genomics
 
Francisco Pardo
Employment - Reveal Genomics
 
Olivia D'Amico
No Relationships to Disclose
 
Alba Martini
No Relationships to Disclose
 
Ross Kusmick
No Relationships to Disclose
 
Nabihah Tayob
No Relationships to Disclose
 
Emanuel Petricoin
Leadership - Ceres Nanosciences; Perthera
Stock and Other Ownership Interests - Ceres Nanosciences; Perthera
Consulting or Advisory Role - Ceres Nanosciences; DAiNA, Inc.; Ignite Proteomics, Inc.; Perthera; Targeted Biosciences, Inc.
Research Funding - Ceres Nanosciences (Inst); Deciphera; G1 Therapeutics (Inst); Genentech (Inst); Mirati Therapeutics (Inst); SpringWorks Therapeutics
Patents, Royalties, Other Intellectual Property - NIH Patents Licensing Fee Distribution/Royalty; University assigned patent licensing fee/royalty
Travel, Accommodations, Expenses - Ceres Nanosciences; Perthera
 
Aleix Prat
Employment - Reveal Genomics
Leadership - Reveal Genomics
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - AstraZeneca; Daiichi Sankyo; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Novartis; Oncolytics; Pfizer; Roche
Research Funding - AstraZeneca; Daiichi Sankyo; Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; TNBC-DX
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Nancy Lin
Stock and Other Ownership Interests - Artera
Consulting or Advisory Role - Artera; AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Eisai; Johnson & Johnson/Janssen; Menarini; Olema Pharmaceuticals; Pfizer; Seagen
Research Funding - Genentech (Inst); Merck (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Zion Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases; Royalties, Jones & Bartlett
Travel, Accommodations, Expenses - AstraZeneca; Olema Pharmaceuticals
 
Sara Tolaney
Consulting or Advisory Role - AADi; Ambrx; Artios Biopharmaceuticals; Arvinas; AstraZeneca; Bayer; BeiGene; Bicycle Therapeutics; BioNTech; Blueprint Medicines; Bristol-Myers Squibb; Circle Pharma; Cullinan Oncology; Daiichi Sankyo; eFFECTOR Therapeutics; Eisai; Genentech; Hengrui Pharmaceutical (USA); Immunomedics/Gilead; Incyte; Jazz Pharmaceuticals; Johnson & Johnson; Launch Therapeutics; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Reveal Genomics; Sanofi; Seagen; Sumitovant Biopharma; Summit Therapeutics; Systimmune; Tango Therapeutics; Zentalis; Zuellig Pharma; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo; Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Menarini/Stemlin (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Arvinas; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Pfizer; Sanofi
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Gilead Sciences